SMS Group
VC Fund
Düsseldorf, Germany
SMS Group is a VC fund in Düsseldorf focused on Mining and Medical. SMS Group offers quality plants, machinery and services to the metallurgical firms for steel, aluminum, copper and metals.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries SMS Group invests in
Stages SMS Group invests in
Countries SMS Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series A
- $6.8M–$105M
Investment Focus
Industry
- Mining 1 (25%)
- Medical 1 (25%)
- Health Care 1 (25%)
- Therapeutics 1 (25%)
- Manufacturing 1 (25%)
Stage
- Series A 2 (50%)
- Series B 1 (25%)
- Series C 1 (25%)
Country
- Sweden 1 (25%)
- Germany 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Paul Lucci
User Interface Designer
|
User Interface Designer | Total investments: 0 | Find email | |
|
Samuel Hargestam
Co-Founder
|
Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Stegra
|
H2 Green Steel helps to build a large-scale steel factory based on a fossil-free manufacturing process targeting large European OEMs.The plant will be built in northern Sweden, in Boden, offering unique conditions for cost-competitive fossil-free steel production. The project includes a giga-scale green hydrogen plant as an integrated part of thesteel production facility. Production will begin in 2024 and by 2030, H2GS will have an annual production capacity of five million tons of high-quality steel. | $105M / Series A / May 24, 2021 | |
OMEICOS Therapeutics
|
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $18.6M / Series C / Nov 02, 2018 | |
|
OMEICOS Therapeutics
|
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $9.1M / Series B / Mar 01, 2017 | |
|
OMEICOS Therapeutics
|
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $6.8M / Series A / Apr 15, 2015 |
Co-Investors
KfW
3 deals together
VC Fonds Technologie Berlin
3 deals together
Vesalius Biocapital Partners
3 deals together
HTGF (High-Tech Gruenderfonds)
2 deals together
Altor
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SMS Group invest in?
SMS Group invests primarily in Mining, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SMS Group's check size?
SMS Group typically joins rounds of $6.8M–$105M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SMS Group participates in.
How do I contact SMS Group?
Public channels for SMS Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SMS Group?
The team at SMS Group includes Paul Lucci (User Interface Designer) and Samuel Hargestam (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
